WESTLAKE VILLAGE, Calif. --(BUSINESS WIRE)--Nov. 16, 2026-- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced that Bradley Burnam, Chief Executive Officer, will deliver a company
Completed GX-03 Stage 1/Phase 2a Trial: 59.3% of GX-03 Patients Achieved Clear or Almost Clear Skin After Four Weeks, Compared with 30.4% Receiving Vehicle Larger Phase 2b Atopic Dermatitis Trial Continues, Informed by Findings from Completed Stage 1/Phase 2a Building on GX-03 Momentum, Turn
Annual Awards Program Recognizes Breakthrough Life Sciences & Biotechnology Innovation Around the World WESTLAKE VILLAGE, Calif. --(BUSINESS WIRE)--Nov. 5, 2026-- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for
WESTLAKE VILLAGE, Calif. --(BUSINESS WIRE)--Oct. 21, 2026-- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced that Bradley Burnam, Chief Executive Officer, and Stephen M.
WESTLAKE VILLAGE, Calif. --(BUSINESS WIRE)--Sep. 10, 2026-- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today announced that Bradley Burnam, Chief Executive Officer, and Stephen M.
Brings internationally recognized expertise in immunology, cytokine biology, host-microbe interactions and public health WESTLAKE VILLAGE, Calif. --(BUSINESS WIRE)--Sep. 9, 2026-- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic
In-vivo study showed GX-03 reduced IL-36, a key early driver of the inflammatory cascade, by approximately 50%, IL-31, a major driver of itch, by nearly 68%, and IL-4, an important inflammatory cytokine, by 16.7% Findings support Turn’s approach of acting earlier in the inflammatory process, before
Interim Analysis Supports Expansion of GX-03 Phase 2 Study to a Broader Population of Atopic Dermatitis Patients, Including Patients with Moderate-to-Severe Lesions but Lower Overall Disease Extent Dr. Stephen M. Hahn, Former FDA Commissioner, Appointed Executive Clinical and Regulatory Lead First
Turn Therapeutics Returns to Nasdaq to Highlight Its Progress Since Its October 2025 Direct Listing WESTLAKE VILLAGE, Calif. --(BUSINESS WIRE)--Jul. 28, 2026-- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory
Clinically meaningful efficacy observed across a broader spectrum of atopic dermatitis supports expansion of the ongoing Phase 2 program to prospectively evaluate patients across the full range of disease severity as defined by the Eczema Area and Severity Index (EASI) Comprehensive interim review